Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.80 |
| ▸ | HPGDS | O60760 | 8/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046841 | 0.89 | MAOB (0.78) | MAOB | |
| SCHEMBL16047395 | 0.89 | MAOB (1.00) | MAOBHPGDS | |
| SCHEMBL1040763 | 0.88 | MAOB (0.80) | MAOBHPGDS | |
| SCHEMBL16047063 | 0.88 | MAOB (0.81) | MAOB | |
| SCHEMBL16048275 | 0.88 | MAOB (0.73) | MAOBMRGPRX4 | |
| SCHEMBL20377589 | 0.87 | MRGPRX4 (0.62) | MAOBHPGDSMRGPRX4 | |
| SCHEMBL20386574 | 0.87 | MAOB (0.70) | MAOBHPGDS | |
| Hydrochloric Acid SCHEMBL6312857 | 0.87 | MAOB (0.78) | MAOBHPGDS | |
| SCHEMBL16046769 | 0.86 | MAOB (0.80) | MAOB | |
| SCHEMBL16047706 | 0.86 | MAOB (0.81) | MAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | claimed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | claimed |
| US-20160074377-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC | 2016-03-17 | — | — | US | claimed |
| EP-2970125-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2016-01-20 | — | — | EP | claimed |
| US-9102674-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-08-11 | — | — | US | claimed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | claimed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | claimed |
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | disclosed |
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-9956213-B2 | Substituted naphthyridine and quinoline compounds as MAO inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-05-01 | — | — | US | disclosed |
| US-20170312263-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2017-11-02 | — | — | US | disclosed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-10-23 | — | — | US | disclosed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014158916-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE LLC | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074377-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885HPGDS 4614/4885MRGPRX4 1582/4885 |
| US-20170312263-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885HPGDS 4623/4885MRGPRX4 1565/4885 |
| US-20140275548-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885HPGDS 4614/4885MRGPRX4 1582/4885 |
| US-20140315944-A1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | MAOB, MAOA, PNMT | MAOB 1/4885HPGDS 4623/4885MRGPRX4 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.